Erlotinib: the first biologic in the management of pancreatic cancer

Bibliography

• Brand RE, Tempero MA. Pancreatic cancer. Curr Opin Oncol 1998;10:362-66
   PubMedGoogle Scholar
• Wanebo HJ, Vezeridis MP. Pancreatic carcinoma in perspective. A continuing challenge. Cancer 1996;78:580-91
   PubMed Web of Science ®Google Scholar
• Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefits with gemcitabine as first-line therapy for pts with advanced pancreatic cancer: a randomized trial. J Clin Oncol 1997;15:2403-13
   PubMed Web of Science ®Google Scholar
• Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19:32s-40s
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37
   PubMed Web of Science ®Google Scholar
• Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002;7(Suppl 4):2-8
   PubMed Web of Science ®Google Scholar
• Xiong HQ, Abbruzzese JL. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 2002;29(5 Suppl 14):31-7
   PubMed Web of Science ®Google Scholar
• Yamanaka Y, Friess H, Kobrin MS, et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993;13:565-9
   PubMed Web of Science ®Google Scholar
• Ueda S, Ogata S, Tsuda H, et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004;29:e1-8
   PubMedGoogle Scholar
• Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000;6:1936-48
   PubMed Web of Science ®Google Scholar
• Buchsbaum DJ, Bonner JA, Grizzle WE, et al. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 2002;54:1180-93
   PubMed Web of Science ®Google Scholar
• Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004;22:2610-6
   PubMed Web of Science ®Google Scholar
• Philip PA, Benedetti J, Fenoglio-Preiser C, et al. Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):LBA4509
   Web of Science ®Google Scholar
• Kullmann F, Hollerbach S, Dollinger M, et al. Cetuximab plus gemcitabine–oxaliplatin (GEMOXCET) in 1st line metastatic pancreatic cancer [abstract 128]. First results from a multicenter phase II study. ASCO Gastrointestinal Cancers Symposium; 2007
   Google Scholar
• Graeven U, Kremer B, Sudhoff T, et al. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer 2006;94:1293-9
   PubMed Web of Science ®Google Scholar
• Strumberg D, Scheulen ME, Hilger RA, et al. Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, as monotherapy in patients with locally advanced or metastatic pancreatic cancer (PC) [abstract 12504]. ASCO Annual Meeting; 2006
   Google Scholar
• National Cancer Institute (NCI) website. Available from: http://www.cancer.gov [Accessed 23 January 2008]
   Google Scholar
• Herbst R. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin Investig Drugs 2002;116:837-49
   Google Scholar
• Ng SS, Tsao MS, Nicklee T, Hedley DW. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 2002;1:777-83
   PubMed Web of Science ®Google Scholar
• Li J, Kleeff J, Giese N, et al. Gefitinib (‘Iressa’, ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int J Oncol 2004;25:203-10
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-79
   PubMed Web of Science ®Google Scholar
• Dragovich T, Patnaik A, Rowinsky E, et al. A Phase I B trial of gemcitabine and erlotinib HCL in patients with advanced pancreatic adenocarcinoma and other potentially responsive malignancies [abstract 895]. ASCO Annual Meeting; 2003
   Google Scholar
• Porterfield BW, Dragovich T, Patnaik A, et al. Erlotinib + gemcitabine in patients with unresectable pancreatic carcinoma: Results from a Phase IB trial [abstract 4110]. ASCO Annual Meeting; 2004
   Google Scholar
• Tarceva website. Available from: www.tarceva.com [Accessed 23 January 2008]
   Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25(15):1960-6
   PubMed Web of Science ®Google Scholar
• Epelbaum R, Schnaider J, Gluzman A, Figer A. Erlotinib as a single-agent therapy in patients with advanced pancreatic cancer [abstract 202]. Gastrointestinal Cancers Symposium; 2007
   Google Scholar
• Ko H, Dito E, Schillinger B, et al. A Phase II study of bevacizumab and erlotinib in patients with gemcitabine-refractory metastatic adenocarcinoma of the pancreas [abstract 187]. Gastrointestinal Cancers Symposium; 2007
   Google Scholar
• Kulke MH, Blaszkowsky LS, Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007;25(30):4787-92
   PubMed Web of Science ®Google Scholar
• Kindler H, Bylow K, Hochster H, et al. A randomized Phase II study of bevacizumab and gemcitabine plus cetuximab or erlotinib in patients with advanced pancreatic cancer: a preliminary analysis [abstrsct 4040]. ASCO Annual Meeting; 2006
   Google Scholar
• Gómez-Martín J, Camara B, Rubio M, et al. A phase I study of erlotinib, bevacizumab, and gemcitabine in patients with advanced pancreatic cancer [abstract 199]. Gastrointestinal Cancers Symposium; 2007
   Google Scholar
• Starling N, Watkins D, Chau I, et al. A phase I study of a chemotherapy doublet (gemcitabine plus capecitabine [GemCap]), combined with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma: The TARGET Trial [abstract 141]. Gastrointestinal Cancers Symposium; 2008
   Google Scholar
• Duffy A, Kortmansky J, Schwartz GK, et al. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 2008;19(1):86-91
   PubMedGoogle Scholar
• Shadad F, Matin K, Evans T, et al. Phase II study of gefitinib and docetaxel as salvage therapy in patients (pts) with advanced pancreatic adenocarcinoma (APC) [abstract 4120]. ASCO Annual Meeting; 2006
   Google Scholar
• Fountzilas G, Murray S, Xiros N, et al. Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer A phase II trial. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):15016
   Google Scholar
• Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3296-302
   PubMed Web of Science ®Google Scholar
• Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002;87:161-7
   PubMed Web of Science ®Google Scholar
• Cheverton P, Friess H, Andras C, et al. Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naïve patients with advanced pancreatic cancer (APC) ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004;22(14S Suppl):4005
   Google Scholar
• Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20(15):3270-5
   PubMed Web of Science ®Google Scholar
• Reiss H, Helm A, Niedergethmann M, et al. A randomized, prospective, multicenter, Phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid versus. gemcitabine in patients with advanced pancreatic cancer. ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(16S Suppl):LBA4009
   Google Scholar
• Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, Phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212-7
   PubMed Web of Science ®Google Scholar
• Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22(18):3776-83
   PubMed Web of Science ®Google Scholar
• Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III trial. J Clin Oncol 2005;23:3509-16
   PubMed Web of Science ®Google Scholar
• Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B [abstract 108]. CALGB ASCO Gastrointestinal Cancers Symposium; 2007
   Google Scholar
• Cunningham D, Chau I, Stocken D, et al. Phase III randomized comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer [abstract PS11]. Presented at: European Cancer Conference (ECCO) 13; 2005 October 30 – November 3; Paris, France
   Google Scholar
• Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212-7
   PubMed Web of Science ®Google Scholar
• Poplin E, Levy DE, Berlin J, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose rate infusion) versus gemcitabine plus oxaliplatin (GEMOX) in patients with advanced pancreatic cancer ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2006;24(18S Suppl):LBA4004
   Google Scholar
• Tejpar S, Peeters M, Humblet Y, et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):4037
   Web of Science ®Google Scholar
• Moore MJ, da Cunha Santos G, Kamel-Reid S, et al. The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with Erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):4521
   Google Scholar
• Huang ZQ, Buchsbaum DJ, Raisch KP, et al. Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. J Surg Res 2003;111:274-83
   PubMed Web of Science ®Google Scholar
• Baerman KM, Caskey LS, Dasi F, et al. EGFR/HER2 targeted therapy inhibits growth of pancreatic cancer cells [abstract 84]. ASCO Annual Meeting; 2005
   Google Scholar
• Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82
   PubMed Web of Science ®Google Scholar
• Bruell D, Stocker M, Huhn M, et al. The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int J Oncol 2003;23:1179-86
   PubMed Web of Science ®Google Scholar
• Reusch U, Sundaram M, Davol PA, et al. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res 2006;12:183-90
   PubMed Web of Science ®Google Scholar